-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Qichacha APP shows that Jiangsu Lerun Contact Lens .
, L.
has undergone industrial and commercial chang.
The original shareholders Jiangsu Hongyi Garden Construction Engineering .
, L.
and Danyang Xintongqiu Optical Glasses .
, L.
withdrew, and the new shareholder Yuyue Medical .
, L.
held 100 shar.
.
According to the data, Lerun Contact Lenses was established on July 11, 201 Its business scope includes glasses and accessories, accessories, eye care solution, preservation solution, cleaning solution, wholesale and retail of medical equipment,e.
It is understood that this is not the first time that Yuyue Medical has made an acquisition in the field of ophthalmolo.
Previously, Yuyue Medical acquired the equity of Suzhou Liuliu Vision Technology and Jiangsu Vision Technology at a price of 34223 million yuan and 42 million yuan respective.
Regarding the frequent increase in the ophthalmology market, Yuyue Medical has publicly stated that ophthalmic medical device products and contact lens-related products have become its strategically planned incubation busine.
In the future, Yuyue Medical will actively promote the brand, technology and business of ophthalmic-related produc.
common developme.
In fact, the current myopia rate in China is about 50%, much higher than the global avera.
As one of the countries with the highest incidence of myopia in the world, it is foreseeable that the Chinese glasses market has huge potential in the future, and it is also expected to attract a large number of enterprises to increase their layo.
It is understood that because contact lenses have different types, degrees, cycles, diameters, colors, and patterns, the products can meet the needs of consumers in different occasions and many personalized, and the products are relatively ri.
In recent years, the market size of contact lenses has been increasing year by ye.
According to data, the sales of contact lenses in China in 2020 will reach 167 billion yuan, a year-on-year increase of 1
Affected by the epidemic, the growth rate has declin.
However, by 2021, the growth rate of the market size of China's contact lenses will recover to 168%, reaching 181 billion yuan, and it will continue to gr.
Ophthalmology is mainly divided into three major sections: ophthalmic medical treatment, ophthalmic equipment and ophthalmic dru.
The product category is very ri.
In addition to contact lenses, the current market for orthokeratology lenses, intraocular lenses (IOL), phakic intraocular lenses (ICL), and therapeutic drugs has also begun to show great development potenti.
And out of optimism about the market prospects, in addition to Yuyue Medical, a large number of domestic companies are increasing their layo.
As of April 12 this year, Guangzheng Ophthalmology announced that in order to further implement the strategic development plan of "focusing on the ophthalmic medical business and accelerating the integration of auxiliary industries", the company plans to sell part of the equity of Xintianshan, a wholly-owned subsidiary, and cooperate with Fujian Shencheng Sign the "Letter of Intent for Equity Transfe.
The company stated that the sale of this business will help to accelerate the company's transformation and upgrading, and further implement the company's development strategic goal of "Juli ophthalmic medical busines.
On February 17, the China Drug Clinical Trial Registration and Information Publicity Platform showed that Zhaoke Ophthalmology Company has launched a Phase 3 clinical trial of atropine sulfate eye drops (NVK-002) for delaying the progression of myopia in children, which is planned to be conducted in Chi.
526 patients were enroll.
According to public information, NVK-002 is a sterile, preservative-free, low-concentration atropine eye drop developed by Nevakar, which is intended to be developed for the control of myopia progression in children and adolescen.
It is worth mentioning that according to incomplete statistics, there are currently more than 30 new domestic ophthalmic drugs (22 category 1 new drugs) that are in the stage of clinical application and above, of which 3 new drugs from Hengrui are expected to be launched; In terms of 10 ophthalmic drugs, no first imitation has been approved, and Kelun, Yangzijiang, e.
have been deployed; in addition, 10 eye drops have been reviewed by companies, and 4 have been included in the national procureme.
The industry believes that with the continuous increase of domestic developers' investment in the research and development of ophthalmic drugs and devices, and the continuous improvement of innovation capabilities, local pharmaceutical companies will continue to make breakthroughs in the field of ophthalmic treatment, and more domestic innovative ophthalmic drugs and ophthalmic devices will gradually emerge, benefiting more and more peop.
more and more patien.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
, L.
has undergone industrial and commercial chang.
The original shareholders Jiangsu Hongyi Garden Construction Engineering .
, L.
and Danyang Xintongqiu Optical Glasses .
, L.
withdrew, and the new shareholder Yuyue Medical .
, L.
held 100 shar.
.
According to the data, Lerun Contact Lenses was established on July 11, 201 Its business scope includes glasses and accessories, accessories, eye care solution, preservation solution, cleaning solution, wholesale and retail of medical equipment,e.
It is understood that this is not the first time that Yuyue Medical has made an acquisition in the field of ophthalmolo.
Previously, Yuyue Medical acquired the equity of Suzhou Liuliu Vision Technology and Jiangsu Vision Technology at a price of 34223 million yuan and 42 million yuan respective.
Regarding the frequent increase in the ophthalmology market, Yuyue Medical has publicly stated that ophthalmic medical device products and contact lens-related products have become its strategically planned incubation busine.
In the future, Yuyue Medical will actively promote the brand, technology and business of ophthalmic-related produc.
common developme.
In fact, the current myopia rate in China is about 50%, much higher than the global avera.
As one of the countries with the highest incidence of myopia in the world, it is foreseeable that the Chinese glasses market has huge potential in the future, and it is also expected to attract a large number of enterprises to increase their layo.
It is understood that because contact lenses have different types, degrees, cycles, diameters, colors, and patterns, the products can meet the needs of consumers in different occasions and many personalized, and the products are relatively ri.
In recent years, the market size of contact lenses has been increasing year by ye.
According to data, the sales of contact lenses in China in 2020 will reach 167 billion yuan, a year-on-year increase of 1
Affected by the epidemic, the growth rate has declin.
However, by 2021, the growth rate of the market size of China's contact lenses will recover to 168%, reaching 181 billion yuan, and it will continue to gr.
Ophthalmology is mainly divided into three major sections: ophthalmic medical treatment, ophthalmic equipment and ophthalmic dru.
The product category is very ri.
In addition to contact lenses, the current market for orthokeratology lenses, intraocular lenses (IOL), phakic intraocular lenses (ICL), and therapeutic drugs has also begun to show great development potenti.
And out of optimism about the market prospects, in addition to Yuyue Medical, a large number of domestic companies are increasing their layo.
As of April 12 this year, Guangzheng Ophthalmology announced that in order to further implement the strategic development plan of "focusing on the ophthalmic medical business and accelerating the integration of auxiliary industries", the company plans to sell part of the equity of Xintianshan, a wholly-owned subsidiary, and cooperate with Fujian Shencheng Sign the "Letter of Intent for Equity Transfe.
The company stated that the sale of this business will help to accelerate the company's transformation and upgrading, and further implement the company's development strategic goal of "Juli ophthalmic medical busines.
On February 17, the China Drug Clinical Trial Registration and Information Publicity Platform showed that Zhaoke Ophthalmology Company has launched a Phase 3 clinical trial of atropine sulfate eye drops (NVK-002) for delaying the progression of myopia in children, which is planned to be conducted in Chi.
526 patients were enroll.
According to public information, NVK-002 is a sterile, preservative-free, low-concentration atropine eye drop developed by Nevakar, which is intended to be developed for the control of myopia progression in children and adolescen.
It is worth mentioning that according to incomplete statistics, there are currently more than 30 new domestic ophthalmic drugs (22 category 1 new drugs) that are in the stage of clinical application and above, of which 3 new drugs from Hengrui are expected to be launched; In terms of 10 ophthalmic drugs, no first imitation has been approved, and Kelun, Yangzijiang, e.
have been deployed; in addition, 10 eye drops have been reviewed by companies, and 4 have been included in the national procureme.
The industry believes that with the continuous increase of domestic developers' investment in the research and development of ophthalmic drugs and devices, and the continuous improvement of innovation capabilities, local pharmaceutical companies will continue to make breakthroughs in the field of ophthalmic treatment, and more domestic innovative ophthalmic drugs and ophthalmic devices will gradually emerge, benefiting more and more peop.
more and more patien.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
